EUVIMEDEUVIMED entdecken
ValidierungsstudieMultizentrische StudieOpen Access · CC BY 4.0

TGx-DDI (toxicogenomic DNA damage-inducing) biomarker validation: multi-site ring trial supporting regulatory use

Xiaotong Wang iD, Christine E Crute iD, Ashley Allemang, Jiri Aubrecht, Florence Burleson, Yasmin Dietz-Baum, Lena Dorsheimer, Albert J Fornace iD, Roland Frötschl iD, Ulrike Hemmann, Constance A Mitchell iD, Stefan Pfuhler und 5 weitere

Toxicological Sciences · 2025

DOI: 10.1093/toxsci/kfaf138 ↗

Kurz gefasst

Validierungsstudie in der Zeitschrift Toxicological Sciences, 2025. Verfasst von Xiaotong Wang und 16 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biology, University of Ottawa, Ottawa, ON K1N 9A7, Canada. Hauptthemen laut MEDLINE: DNA Damage, Toxicogenetics, Mutagens. Die Arbeit nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Emerging Systems Toxicology for the Assessment of Risk, Canada Research Chairs Program, FDA HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Standard in vitro genotoxicity assays often suffer from low specificity, leading to irrelevant positive findings that require costly in vivo follow-up studies. The TGx-DDI (Toxicogenomic DNA Damage-Inducing) transcriptomic biomarker was developed to address this limitation by identifying DNA damage-inducing compounds through gene expression profiling in human TK6 lymphoblastoid cells. To qualify TGx-DDI as a reliable, reproducible biomarker for augmenting genotoxicity hazard assessment, a multi-site ring-trial was conducted across four laboratories using 14 blinded test compounds and standardized protocols. TK6 cells were exposed to three concentrations of each compound, followed by RNA extraction and digital nucleic acid counting using the NanoString nCounter platform. A three-pronged bioinformatics approach—Nearest Shrunken Centroid Probability Analysis, Principal Component Analysis, and Hierarchical Clustering—was used to assign DDI or non-DDI classifications. TGx-DDI demonstrated 100% sensitivity, 86% specificity, and 91% accuracy in distinguishing DDI from non-DDI compounds under validated test conditions. High interlaboratory concordance was observed (agreement coefficients ≥0.61), and transcriptomic data showed strong cross-site correlation (Pearson r > 0.84). The biomarker reproducibly classified test agents even when conducted across study sites. These results demonstrate that TGx-DDI is a robust and reproducible transcriptomic biomarker that enhances the specificity of genotoxicity testing by distinguishing biologically relevant DNA damage responses. Its integration into genotoxicity testing strategies can support regulatory decision-making, reduce unnecessary animal use, and improve the assessment of human health risks.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

DNA DamageToxicogeneticsMutagensHumansMutagenicity TestsBiomarkersGene Expression ProfilingReproducibility of ResultsCell LineTranscriptome

Stichwörter der Autor:innen

TGx-DDIbiomarkergenotoxicityin vitronew approach methodologies (NAMs)toxicogenomicsvalidation

Substanzen

BiomarkersMutagens

Autor:innen und Institutionen

  • Department of Biology, University of Ottawa, Ottawa, ON K1N 9A7, Canada.
  • Health and Environmental Sciences Institute (HESI Global), Washington, DC 20005, United States.
  • The Procter & Gamble Company, Mason, OH 45202, United States.
  • Department of Oncology, Georgetown University Medical Center, Washington, DC 20057, United States.
  • Burleson Research Technologies, Inc, Morrisville, NC 27560, United States.
  • Research and Development, Translational Medicine Unit, Sanofi-Aventis Deutschland GmbH, Frankfurt am Main, HE 65926, Germany.

ORCID-Profile: Xiaotong Wang, Christine E Crute, Albert J Fornace, Roland Frötschl, Constance A Mitchell, Syril Pettit, Carole L Yauk, Heng-Hong Li

Förderung

  • Emerging Systems Toxicology for the Assessment of Risk
  • Canada Research Chairs Program
  • FDA HHS
  • Drug Development Tool Team
  • Health and Environmental Sciences Institute's
  • Health and Environmental Sciences Institute’s

Zitieren

APA

Wang, X., Crute, C. E., Allemang, A., Aubrecht, J., Burleson, F., Dietz-Baum, Y., Dorsheimer, L., Fornace, A. J., Frötschl, R., Hemmann, U., Mitchell, C. A., Pfuhler, S., Williams, A., Lin, L. Y., Pettit, S., Yauk, C. L., & Li, H. H. (2025). TGx-DDI (toxicogenomic DNA damage-inducing) biomarker validation: multi-site ring trial supporting regulatory use. Toxicological Sciences. https://doi.org/10.1093/toxsci/kfaf138

Vancouver

Wang X, Crute CE, Allemang A, Aubrecht J, Burleson F, Dietz-Baum Y, et al. TGx-DDI (toxicogenomic DNA damage-inducing) biomarker validation: multi-site ring trial supporting regulatory use. Toxicological Sciences. 2025. doi:10.1093/toxsci/kfaf138

BibTeX
@article{Wang2025,
  author = {Wang, Xiaotong and Crute, Christine E and Allemang, Ashley and Aubrecht, Jiri and Burleson, Florence and Dietz-Baum, Yasmin and Dorsheimer, Lena and Fornace, Albert J and Frötschl, Roland and Hemmann, Ulrike and Mitchell, Constance A and Pfuhler, Stefan and Williams, Andrew and Lin, Lorreta Yun-Tien and Pettit, Syril and Yauk, Carole L and Li, Heng-Hong},
  title = {TGx-DDI (toxicogenomic DNA damage-inducing) biomarker validation: multi-site ring trial supporting regulatory use},
  journal = {Toxicological Sciences},
  year = {2025},
  doi = {10.1093/toxsci/kfaf138}
}
Kostenlos starten →